Clinical trial · Observational
Prospective Post Y90 Liver Hypertrophy
Prospective Study of Early Contra-lateral Liver Lobar Hypertrophy After Unilobar Y-90 Selective Internal Radiation Therapy (SIRT) in Patients With Hepatocellular Carcinoma (HCC)
NCT02783261CI-TRIAL-00025952unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients undergoing Y90 radioembolization to will be followed prospectively with CT volumetry to determine post-Y90 rate of liver hypertrophy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Hypertrophy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT volumetric measurement after Y90 radioembolization | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Post Y90 hypertrophy measurement
- description
- All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
- interventionNames
- Other: CT volumetric measurement after Y90 radioembolization
Primary outcomes (1)
- measure
- liver hypertrophy
- timeFrame
- CT volumetry will be performed at: 1) within 1 month of radioembolization; 2) 4 to 6 weeks and 3) 8 to12 weeks after SIRT.
- description
- Primary outcomes: The rate of change in volume of the contralateral liver volume from baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with HCC who are to receive SIRT * The diagnosis of HCC is made based on current diagnostic criteria i.e. a characteristic appearance on contrast-enhanced quadriphasic CT scan and/or MRI, raised serum AFP levels and the presence of known risk factors * Patients with tumor confined in the right/left lobe who will receive unilobar SIRT to the right/left hepatic artery * All adult patients above 21 are eligible for the study * Able to provide informed consent Patients must meet all the above inclusion criteria to be enrolled into the study Exclusion Criteria: Any patient with the following exclusion criteria will not be eligible for the study: * Patients who received SIRT not confined to the left or right lobe * Patients who received other concomitant treatment * Patients with bilobar disease at the time of treatment
References
Publications (0)
Data not yet available
No reference posted for this study.